

CORRECTION

Correction: Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients

Eiichiro Nagata, Mieko Ogino, Kounosuke Iwamoto, Yasuhisa Kitagawa, Yasuo Iwasaki, Fumihito Yoshii, Joh-E. Ikeda, ALS Consortium Investigators

Notice of Republication

This article was republished on March 14, 2016, to correct the captions of Figs 3–7 and Figs 9–10 and figure citations in the Discussion section. Please download this article again to view the correct version. The originally published, uncorrected article and the republished, corrected articles are provided here for reference.

Supporting Information

S1 File. Originally published, uncorrected article.
(PDF)

S2 File. Republished, corrected article.
(PDF)

Reference

1. Nagata E, Ogino M, Iwamoto K, Kitagawa Y, Iwasaki Y, Yoshii F, et al. (2016) Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients. *PLoS ONE* 11(2): e0149509. doi:[10.1371/journal.pone.0149509](https://doi.org/10.1371/journal.pone.0149509) PMID: [26910108](https://pubmed.ncbi.nlm.nih.gov/26910108/)



CrossMark
click for updates

OPEN ACCESS

Citation: Nagata E, Ogino M, Iwamoto K, Kitagawa Y, Iwasaki Y, Yoshii F, et al. (2016) Correction: Bromocriptine Mesylate Attenuates Amyotrophic Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in Japanese Patients. *PLoS ONE* 11(3): e0152845. doi:[10.1371/journal.pone.0152845](https://doi.org/10.1371/journal.pone.0152845)

Published: March 28, 2016

Copyright: © 2016 Nagata et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.